Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy Plus Nimotuzumab vs Radiotherapy Alone in Platinum-Ineligible LA-HNSCC
NCT07333274Phase 3Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Shandong Cancer Hospital. Started Jan 2026; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07333274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333274.